Compare Novartis AG (NVS) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Organon & Co. Common Stock — how do they compare? Novartis AG trades at $148.12 (market cap $271.82B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Novartis AG is far larger — about 75.1× Organon & Co. Common Stock's market cap, and Novartis AG pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Organon & Co. Common Stock for 0 Days on average.
| NVS | OGN | |
|---|---|---|
Market Cap | $271.82B | $3.62B |
Volume | 1,841,354 | 2,892,999 |
Sector | Health | Health |
52-Week High | $168.62 | $13.81 |
52-Week Low | $121.80 | $5.70 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $313.15B | $11.04B |
Dividend Yield | 3.33% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVS trades at $146.88, up 2.11% today, with a bearish technical signal from moving averages and an overbought RSI. The company reported revenue of $56.67B in 2025, with a net income margin of 22.5%, and recently announced a $7.8B licensing deal with China's Abogen for RNA-based therapy. Earnings have been mixed, beating in Q4 2025 and Q2 2026 but missing in Q1 2026.
The outlook is cautious due to recent clinical trial setbacks and investor scrutiny of M&A strategy. Analyst consensus is a $146 price target with a hold-heavy rating. Risks include pipeline failures and competitive pressures, but strong cash flow and profitability provide support.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
